{
    "nct_id": "NCT06472245",
    "official_title": "A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor",
    "inclusion_criteria": "1. Male or female, aged â‰¥ 18 years\n2. Patients expressing HLA-A2 phenotype in blood by pre-screening central laboratory\n3. Patients with histologically or cytologically squamous or non-squamous documented NSCLC, metastatic stage at study entry, not eligible for definite surgery or radiation, without EGFR, ALK and ROS1 gene alterations eligible for targeted therapy; other sensitizing mutations known to be immunosensitive are eligible in case of lack of local access to targeted therapy (i.e.; KRAS G12C and BRAF mutations) after Sponsor's agreement\n4. Patients with secondary resistance to ICI;\n\nOther inclusion and exclusion criteria will apply per protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}